The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This brief reviews what we know about the impact of provider consolidation on health care prices and quality and finds that consolidation leads to higher prices with no compelling evidence of commensurate quality improvements.
This analysis examines the impact of COVID-19 on assisted living facilities, including changes in cases and deaths between June and August 2020, using state-reported data on COVID-19. The analysis finds a significant increase in COVID-19 cases and deaths among residents and staff in assisted living facilities over this two-month period. Due to the incomplete nature of state reporting, these numbers are an undercount.
This policy watch examines the likely impact of an executive order signed by President Trump in July 2020 related to prescription drugs, which would use lower international drug prices to set prices for a limited set of drugs in the U.S.
Potential changes in mail service delivery could be a concern for people who receive prescription drugs from mail-order pharmacies. To understand who may be most affected by delays in the delivery of prescription drugs, we analyzed use of mail order in Medicare Part D and large group employer plans, and identified the therapeutic classes and specific drugs with the highest volume of fills by mail-order pharmacies in each market.
In an article in Health Affairs, KFF's Juliette Cubanski, Sarah True and Tricia Neuman, and several other co-authors, explore how often brand-name drugs receive favorable formulary inclusion relative to generics in the Medicare Part D program's prescription drug plans.
This analysis examines the extent of state-level variation in the share of COVID-19 deaths accounted for by older adults, using data from the CDC as of July 22, 2020, for the week ending July 11, 2020.
This brief discusses how drugs provided in inpatient hospital settings are covered and reimbursed for beneficiaries in traditional Medicare under current law. This is relevant for Medicare spending on COVID-19 patients who receive Gilead’s new antiviral drug remdesivir. We discuss the implications for hospitals and the Medicare program of spending on remdesivir.
This analysis examines how states are regulating assisted living facilities in response to the COVID-19 pandemic, based on state-issued guidance for assisted living facilities on visitation, staff screening, and use of personal protective equipment. In addition, we tally state-level data on COVID-19 cases and deaths in assisted living facilities among states reporting such data as of June 8, 2020.
In light of heightened attention to insulin and the Trump Administration’s new Part D model to address out-of-pocket costs for insulin for Medicare beneficiaries, we analyzed out-of-pocket spending on insulin by beneficiaries enrolled in Part D drug plans, variation in Part D plan formulary coverage and tier placement of insulin products, and trends in prices for insulin.
This brief analyzes the distribution of $50 billion in CARES Act funding for providers and shows that the distribution formula selected by the Department of Health and Human Services favored hospitals with a relatively high share of revenue from private insurance. Hospitals that see a smaller share of patients with private insurance and instead see more patients with Medicare or Medicaid received less funding per hospital bed.
© 2026 KFF
